The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is focused exclusively on improving treatment options for people living with Neurofibromatosis type 1-related plexiform neurofibromas. With the goal of therapeutics always in mind, initiatives span research that probes the basic aspects of tumorgenesis through clinical investigations of drugs that have the highest likelihood of having a positive impact for patients. NTAP’s approach is defined by (1) intense collaboration both within and outside of the neurofibromatosis research community and (2) ongoing critical assessment of the existing needs and opportunities for developing effective plexiform neurofibroma therapeutics.